July 6, 2004 — ANN ARBOR, MICH., July 6, 2004 – Michael W. Long, Ph.D., the President and CEO of Velcura Therapeutics™, Inc. announced today that two outstanding Michigan life science professionals have joined the Ann Arbor biotech company that is dedicated to fighting bone disease. "The two women who have joined our team at Velcura Therapeutics are excellent representatives of the talent available here in Michigan," said Dr. Long.

Jan. 5, 2004 — ANN ARBOR, MICH., Jan. 5, 2004 – Michael W. Long, Ph.D., the President and CEO of Velcura Therapeutics™, Inc., recently announced that Julie Glowacki, Ph.D., John Lowe, M.D. and W. Stratford May, M.D., Ph.D. have joined the biotech company’s Scientific Advisory Board (SAB).

Nov. 18, 2003 — ANN ARBOR, MICH., Nov. 18, 2003 – Daniel Chagnovich, Ph.D. has joined Velcura Therapeutics™, Inc. as senior scientist, Bioinformatics. He most recently worked at Pfizer’s Global Research and Development Center in Ann Arbor as a scientist in the Molecular Technologies group.

Oct. 6, 2003 — ANN ARBOR, MICH., Oct. 6, 2003 –Velcura Therapeutics™, Inc. recently was awarded a $224,000 Phase 1 SBIR (Small Business Innovation Research) grant from the National Institute on Aging, National Institutes of Health (NIH).

Dec. 10, 2002 — Lansing, Mich., Dec. 10, 2002 – "Developing new and better therapies for osteoporosis and other bone diseases, Velcura Therapeutics, Inc. is interested in strategic partnerships to speed this process and bring the benefits in translating our scientific research from the laboratory bench to the bedside," said Dr. Michael W. Long, scientific founder and CEO of the biotechnology company that was honored at the Dec. 9 Michigan Investment and Commercialization Success Celebration.